SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology...
The engagement is an additional step in the Company's path towards marketing clearance with the FDABRAINTREE, Mass., Sept. 27, 2023...
Qualigen Therapeutics, Inc. Figure 1A Qualigen Therapeutics, Inc. Figure 1B Qualigen Therapeutics, Inc. Table 1Two posters include data on potential clinical biomarkers...
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society...
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and...
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024FARMINGTON HILLS, Mich., and PITTSBURGH, Sept....
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic...
The first academic center activated to enroll, led by an instrumental investigator who participated in Femasys’ earlier FemBloc studies -FemBloc...
Preliminary Research on Late Life Depression and Accelerated Depression Treatment Protocol will be FeaturedBURLINGTON, Mass. and JERUSALEM, Sept. 27, 2023...
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief...
- Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - Monotherapy arm has...
Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa...
BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining...
Patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist Phase 1 study complete and data will...
WALTHAM, Mass.--(BUSINESS WIRE)--Cytel Inc., provider of quantitative insights and health data analytics to leaders in the life sciences, has acquired...
BOSTON & LONDON--(BUSINESS WIRE)--Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston- and London-based medical technology company, is excited...